Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E
Abstract
Atherosclerosis is strongly associated with dyslipoproteinaemia, and especially with increasing concentrations of low-density lipoprotein and decreasing concentrations of high-density lipoproteins. Its association with increasing concentrations of plasma triglyceride is less clear but, within the mixed hyperlipidaemias, dysbetalipoproteinaemia (Fredrickson type III hyperlipidaemia) has been identified as a very atherogenic entity associated with both premature ischaemic heart disease and peripheral arterial disease. Dysbetalipoproteinaemia is characterized by the accumulation of remnants of chylomicrons and of very low-density lipoproteins. The onset occurs after childhood and usually requires an additional metabolic stressor. In women, onset is typically delayed until menopause. Clinical manifestations may vary from no physical signs to severe cutaneous and tendinous xanthomata, atherosclerosis of coronary and peripheral arteries, and pancreatitis when severe hypertriglyceridaemia is present. Rarely, mutations in apolipoprotein E are associated with lipoprotein glomerulopathy, a condition characterized by progressive proteinuria and renal failure with varying degrees of plasma remnant accumulation. Interestingly, predisposing genetic causes paradoxically result in lower than average cholesterol concentration for most affected persons, but severe dyslipidaemia develops in a minority of patients. The disorder stems from dysfunctional apolipoprotein E in which mutations result…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A standard tool for diagnosing dysbetalipoproteinemia is apoE phenotyping on the basis of immunostaining of 3 major isoforms (apoE2, apoE3, and apoE4) or apoE genotyping.
“A standard tool for diagnosing dysbetalipoproteinemia is apoE phenotyping on the basis of immunostaining of 3 major isoforms (apoE2, apoE3, and apoE4) or apoE genotyping (3, 8, 9 ) .”
From Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping (2016) · cites this paper as [8]
ApoE is a determinant of CVD risk and atherosclerosis.
“Similarly, apoE is a determinant of CVD risk and atherosclerosis.”
From Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping (2016) · cites this paper as [8]
ApoE polymorphisms are associated with other lipid abnormalities and neurological disorders such as Alzheimer disease.
“Moreover, apoE polymorphisms are associated with other lipid abnormalities and neurological disorders such as Alzheimer disease (3, 8, 9 ) .”
From Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping (2016) · cites this paper as [8]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 151 · Cited by 70
- Authors
- Marais, A. D., Solomon, G. A. E., & Blom, D. J.
- Affiliations
- National Health Laboratory Service (ZA)
- University of Cape Town (ZA)
- Corresponding author
- Marais, A. D.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2014-01-09
- Volume
- 51
- Issue
- 1
- Pages
- 46-62
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W2059802803
- Cited by
- 70
- References
- 151
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 11 · 2014: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Reviews in Clinical Laboratory Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- remnant lipoproteins, mixed dyslipidemia, atherosclerosis, xanthoma, lipoprotein glomerulopathy, apolipoprotein E deficiency, LDL receptor binding, hypertriglyceridemia, cardiovascular risk, genetic counseling, diagnosis, fibrates, statins
- MeSH terms
- Apolipoproteins E, Humans, Hyperlipoproteinemia Type III, Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review